File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/22221751.2021.2011623
- WOS: WOS:000735191000001
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Article: A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
Title | A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses |
---|---|
Authors | |
Issue Date | 2021 |
Citation | Emerging Microbes & Infections, 2021, v. 11, p. 147-157 How to Cite? |
Abstract | The repeated emergence of highly pathogenic human coronaviruses as well as their evolving variants highlight the need to develop potent and broad-spectrum antiviral therapeutics and vaccines. By screening monoclonal antibodies (mAbs) isolated from COVID-19-convalescent patients, we found one mAb, 2-36, with cross-neutralizing activity against SARS-CoV. We solved the cryo-EM structure of 2-36 in complex with SARS-CoV-2 or SARS-CoV spike, revealing a highly conserved epitope in the receptor-binding domain (RBD). Antibody 2-36 neutralized not only all current circulating SARS-CoV-2 variants and SARS-COV, but also a panel of bat and pangolin sarbecoviruses that can use human angiotensin-converting enzyme 2 (ACE2) as a receptor. We selected 2-36-escape viruses in vitro and confirmed that K378 T in SARS-CoV-2 RBD led to viral resistance. Taken together, 2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses. Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine. |
Persistent Identifier | http://hdl.handle.net/10722/314427 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, P | - |
dc.contributor.author | Casner, RG | - |
dc.contributor.author | Nair, MS | - |
dc.contributor.author | Yu, J | - |
dc.contributor.author | Guo, Y | - |
dc.contributor.author | Wang, M | - |
dc.contributor.author | Chan, JFW | - |
dc.contributor.author | Cerutti, G | - |
dc.contributor.author | Iketani, S | - |
dc.contributor.author | Liu, L | - |
dc.contributor.author | Sheng, Z | - |
dc.contributor.author | Chen, Z | - |
dc.contributor.author | Yuen, KY | - |
dc.contributor.author | Kwong, PD | - |
dc.contributor.author | Huang, Y | - |
dc.contributor.author | Huang, L | - |
dc.contributor.author | Ho, DD | - |
dc.date.accessioned | 2022-07-22T05:24:20Z | - |
dc.date.available | 2022-07-22T05:24:20Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Emerging Microbes & Infections, 2021, v. 11, p. 147-157 | - |
dc.identifier.uri | http://hdl.handle.net/10722/314427 | - |
dc.description.abstract | The repeated emergence of highly pathogenic human coronaviruses as well as their evolving variants highlight the need to develop potent and broad-spectrum antiviral therapeutics and vaccines. By screening monoclonal antibodies (mAbs) isolated from COVID-19-convalescent patients, we found one mAb, 2-36, with cross-neutralizing activity against SARS-CoV. We solved the cryo-EM structure of 2-36 in complex with SARS-CoV-2 or SARS-CoV spike, revealing a highly conserved epitope in the receptor-binding domain (RBD). Antibody 2-36 neutralized not only all current circulating SARS-CoV-2 variants and SARS-COV, but also a panel of bat and pangolin sarbecoviruses that can use human angiotensin-converting enzyme 2 (ACE2) as a receptor. We selected 2-36-escape viruses in vitro and confirmed that K378 T in SARS-CoV-2 RBD led to viral resistance. Taken together, 2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses. Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine. | - |
dc.language | eng | - |
dc.relation.ispartof | Emerging Microbes & Infections | - |
dc.title | A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses | - |
dc.type | Article | - |
dc.identifier.email | Chan, JFW: jfwchan@hku.hk | - |
dc.identifier.email | Chen, Z: zchenai@hku.hk | - |
dc.identifier.email | Yuen, KY: kyyuen@hkucc.hku.hk | - |
dc.identifier.authority | Chan, JFW=rp01736 | - |
dc.identifier.authority | Chen, Z=rp00243 | - |
dc.identifier.authority | Yuen, KY=rp00366 | - |
dc.identifier.doi | 10.1080/22221751.2021.2011623 | - |
dc.identifier.hkuros | 334614 | - |
dc.identifier.volume | 11 | - |
dc.identifier.spage | 147 | - |
dc.identifier.epage | 157 | - |
dc.identifier.isi | WOS:000735191000001 | - |